Protalix BioTherapeutics, Inc.
| Security | PLX / Protalix BioTherapeutics, Inc. |
| Insider | Yaron Naos |
This page shows the track record and history of Naos Yaron
insider trades in Protalix BioTherapeutics, Inc.. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company.
It is illegal for insiders to make trades in their companies based on material, non-public information ("MNPI"). This does not mean
it is illegal for them to make any
trades in their own companies. However, they must report all trades to the SEC via a Form 4.
Insider Purchases - Short Term Profit Analysis
In this section, we analyze the profitability of every unplanned, open-market insider purchase made by Yaron Naos in PLX / Protalix BioTherapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.
The following table shows the most recent open market purchases that were not part of an automatic trading plan.
| Trade Date | Reported Shares |
Reported Price |
Adjusted Shares |
Adjusted Price |
Cost Basis | Days to Max |
Price at Max |
Max Profit ($) |
Max Return (%) |
|---|---|---|---|---|---|---|---|
| There are no known unplanned open-market trades for this insider |
Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.
Insider Sales - Short Term Loss Analysis
In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made by Yaron Naos in PLX / Protalix BioTherapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.
The following table shows the most recent open market purchases that were not part of an automatic trading plan.
| Trade Date | Reported Shares |
Reported Price |
Adjusted Shares |
Adjusted Price |
Cost Basis | Days to Min |
Price at Min |
Max Loss Avoided ($) |
Max Loss Avoided (%) |
|---|---|---|---|---|---|---|---|
| There are no known unplanned open-market trades for this insider |
Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.
Insider Transaction History
| File Date |
Trade Date |
Form | Insider | Ticker | Security Title | Code | Direct | Exercise Price |
Unit Price |
Units Changed |
Value Changed (1K) |
Remaining Options |
Remaining Shares |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-04 | 2025-09-03 | 4 | Naos Yaron By Trust | PLX | Common Stock | I | 25,000 | 225,817 | ||||||
| 2023-08-17 | 2023-08-15 | 4 | Naos Yaron By Trust | PLX | Common Stock | I | 187,344 | 200,817 | ||||||
| 2020-08-13 | 2020-08-11 | 4 | Naos Yaron | PLX | Stock Options (Right to Buy) | D | 3.59 | 122,656 | 122,656 | |||||
| 2018-09-14 | 2018-09-13 | 4 | Naos Yaron | PLX | Stock Options (Right to Buy) | D | 0.56 | 600,000 | 600,000 | |||||
| 2018-06-08 | 3 | Naos Yaron | PLX | Common Stock | D | 270,688 | ||||||||
| 2018-06-08 | 3 | Naos Yaron By Trust | PLX | Common Stock | I | 328,001 | ||||||||
| 2018-06-08 | 3 | Naos Yaron | PLX | Common Stock | D | 270,688 | ||||||||
| 2018-06-08 | 3 | Naos Yaron By Trust | PLX | Common Stock | I | 328,001 | ||||||||
| 2018-06-08 | 3 | Naos Yaron | PLX | Common Stock | D | 270,688 | ||||||||
| 2018-06-08 | 3 | Naos Yaron By Trust | PLX | Common Stock | I | 328,001 |
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)
